Literature DB >> 10755745

Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules.

K Brebner1, R Phelan, D C Roberts.   

Abstract

RATIONALE: Recent reports have indicated that the gamma-aminobutyric acid (GABA)B agonist baclofen attenuates the reinforcing effects of cocaine.
OBJECTIVES: To further evaluate the effect of baclofen on cocaine self-administration under a fixed ratio (FR) and progressive ratio (PR) schedule of reinforcement.
METHODS: In the first series of experiments, three dose-response curves were generated that examined the effect of three doses of baclofen (1.8, 3.2, or 5.6 mg/kg, i.p.) against four unit-injection doses of cocaine (0.19, 0.38, 0.75, and 1.5 mg/kg per injection) reinforced under a FRI schedule. For comparison, an additional group of rats was pretreated with haloperidol (32, 56, or 100 microg/kg, i.p.). A separate experiment examined the effect of baclofen (1.8, 3.2, or 5.6 mg/kg, i.p.) on responding for concurrently available cocaine or food reinforcement.
RESULTS: Under the FR1 schedule, baclofen suppressed intake of low but not high unit injection doses of cocaine. In contrast to haloperidol, baclofen had no effect on the distribution of inter-injection intervals and, instead, produced long pauses in cocaine self-administration. Baclofen dose dependently reduced cocaine-reinforced responding on a PR schedule; concurrent access to a food-reinforced lever demonstrated that the animals retained the capacity to respond at high rates.
CONCLUSION: The effect of baclofen pretreatment on cocaine self-administration is dependent on the unit injection dose of cocaine and on the response requirements of the schedule.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755745     DOI: 10.1007/s002130050056

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

Review 1.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

2.  Reinforcing efficacy of fat, as assessed by progressive ratio responding, depends upon availability not amount consumed.

Authors:  F H E Wojnicki; R K Babbs; R L W Corwin
Journal:  Physiol Behav       Date:  2010-03-16

Review 3.  Hypocretin/orexin involvement in reward and reinforcement.

Authors:  Rodrigo A España
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 4.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep.

Authors:  Zachary D Brodnik; David L Bernstein; Courtney D Prince; Rodrigo A España
Journal:  Behav Brain Res       Date:  2015-06-03       Impact factor: 3.332

Review 6.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

7.  Effects of extended-access self-administration and deprivation on breakpoints maintained by cocaine in rats.

Authors:  Yu Liu; David C S Roberts; Drake Morgan
Journal:  Psychopharmacology (Berl)       Date:  2005-01-14       Impact factor: 4.530

8.  Baclofen reduces fat intake under binge-type conditions.

Authors:  Ariel Buda-Levin; Francis H E Wojnicki; Rebecca L Corwin
Journal:  Physiol Behav       Date:  2005-09-15

9.  Baclofen, raclopride, and naltrexone differentially reduce solid fat emulsion intake under limited access conditions.

Authors:  R E Rao; F H E Wojnicki; J Coupland; S Ghosh; R L W Corwin
Journal:  Pharmacol Biochem Behav       Date:  2008-02-15       Impact factor: 3.533

10.  Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans.

Authors:  Joshua A Lile; William W Stoops; Timothy S Allen; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2003-09-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.